This study was designed to evaluate serum LC3-II, BCL-2, IL-1β, TGF-β1, and podocin levels in.type 2 diabetes (T2DM) patients with renal dysfunction. Materials176 Turkish subjects were enrolled, of whom 26 were healthy, and 150 had T2DM. Patients.were classified according to albumin urea ratio: 88 patients had macroalbuminuria, 20.patients had microalbuminuria, and 42 had normoalbuminuria. T2DM patients were also.classified into three groups according to proteinuria and eGFR stages. ResultsIncreased serum LC3-II levels in patients with T2DM with increased urinary albumin.extraction and impaired renal functions. There was a strong relationship between serum.LC3-II levels and serum BCL-2, IL-1β, TGF-β1, and Podocin levels. The efficiency of LC3-II as a diagnostic biomarker in the differential diagnosis of DM patients with.macroproteinuria from DM patients with normoproteinuria was 75.4%. ConclusionsIt was thought that increased serum LC3-II levels in T2DM patients with impaired renal.functions may cause renal podocyte damage. In these patients, serum LC3-II levels can be.evaluated as a new biomarker to follow the development of renal damage.